CD4+ T-cell subsets in autoimmunity

Current Opinion in Immunology

Volumn 9, Issue 6, 1997, Pages 872-883

  O'Garra, Anne ^a   Steinman, Lawrence ^b   Gijbels, Koenraad ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b STANFORD UNIVERSITY   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOTOXIN; TRANSFORMING GROWTH FACTOR BETA;

ALLERGY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CYTOKINE RELEASE; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0031446317     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80192-6     Document Type: Article

References (145)

1. McFarland HF: Complexities in the treatment of autoimmune disease. Science 1996, 274:2037-2038.
2. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T: Organ-specific autoimmune diseases induced in mice by elimination of T cell subset I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985, 161:72-87.
3. Mason D, Fowell D: T-cell subsets in autoimmunity. Curr Opin Immunol 1992, 4:728-732.
4. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H: Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305-317.
5. Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319-331.
6. Lafferty KJ, Prowse SJ, Simeonovic CJ: Immunobiology of tissue transplantation: a return to the passenger leukocyte concept Annu Rev Immunol 1983, 1:143-173.
7. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990, 248:1349-1356.
8. Fowell D, Mason D: Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993, 177:627-636,
9. Powrie F: T cells in inflammatory bowel disease: protective, pathologic roles. Immunity 1995, 3:171-174.
10. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
11. Mosmann TR, Coffman RL: Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989, 46:111-147.
12. Liblau R, Singer S, McDevitt H: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995, 16:34-38.
13. Powrie F, Coffman RL: Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993, 14:270-274.
14. O'Garra A, Murphy K: T-cell subsets in autoimmunity. Curr Opin Immunol 1993, 5:880-886.
15. O'Garra A, Murphy K: Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994, 6:458-466.
16. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
17. Constant SL, Bottomly K: Induction of the Th1 and Th2 CD4+ T cell responses: alternative approaches. Annu Rev Immunol 1997, 15:297-322.
18. Hsieh C-S, Macatonia SE, O'Garra A, Murphy KM: T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 1995, 181:713-721.
19. H1 cell development Science 1996, 271:984-987.
20. Locksley RM, Scott P: Helper T-cell subsets in mouse Leishmaniasis: induction, expansion and effector function. Immunol Today 1991, 12.:58-61.
21. Scott B, Liblau R, Degerman S, Marconi L-A, Ogata L, Caton AJ, McDevitt HO, Lo D: A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994, 1:73-82.
22. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994, 76:241-251.
23. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM: Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260:547-549.
24. Manetti R, Parronchi P, Guidizi MG, Piccinni M-P, Maggi E, Trinchieri G, Romagnani S: Natural killer cell stimulatory factor (interleukin 12 [IL-12] induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing cells. J Exp Med 1993, 177:1199-1204.
25. Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance, antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13:251-276.
26. D'Andrea A, Rengaraju M, Valiante NM, Chemini J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, Trinchieri G: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:1387-1398.
27. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh C-S, Culpepper J, Wysocka M, Trinchieri G, Murphy KM, O'Garra A: Dendritic cells produce IL-12 and direct the development of TM cells from naive CD4+ T cells. J Immunol 1995, 154:5071-5079.
28. Szabo S, Dighe AS, Gubler U, Murphy KM: Regulation of the Interleukin (IL)-12β2 Subunit Expression in Developing T Helper 1 (Th1) and Th2 Cells. J Exp Med 1997, 185:817-824.
29. Okamura H, Tsutsul H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Mukuda Y, Hattori K et al.: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995, 378:88-91.
30. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A: IGIF does not drive Th1 development, but synergizes with IL-12 for IFN-γ production, and activates IRAK and NF-κB. Immunity 1997, 7:572-581.
31. Sher A, Coffman RL: Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 1992, 10:385-409.
32. Mosmann TR, Moore KW: The role of IL-10 in cross-regulation of Th1 and Th2 responses. Immunol Today 1991, 12:A49-A53.
33. Moore KW, O'Garra A, Malefyt RDW, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 1993, 11:165-190.
34. Parish CR: The relationship between humoral, cell-mediated immunity. Transplant Rev 1972, 13:35-66.
35. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, Shevach EM, Rocken M: Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994, 180:1961-1966.
36. Sun B, Rizzo LV, Sun SH, Chan CC, Wiggert B, Wilder B, Caspi RR: Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol 1997, 159:1004-1011.
37. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR: IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997, 158:5997-6005.
38. Persson S, Mikulowska A, Narula S, O'Garra A, Holmdahl R: Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996, 44:607-614.
39. Calder VL, Lightman SL: Experimental autoimmune uveoretinitis (EAU) versus experimental allergic encephalomyelitis (EAE): a comparison of T-cell mediated mechanisms. Clin Exp Immunol 1992, 89:165-169.
40. Caspi RR, Kuwabara T, Nussenblatt RB: Characterisation of a suppressor cell line which downgrades experimental autoimmune uveoretinitis in the rat J Immunol 1988, 140:2579-2584.
41. Williams RO, Feldman M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89:9784-9788.
42. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. J Immunol 1992, 77:510-514.
43. Williams RO, Williams DG, Feldman M, Maini RN: Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin Exp Immunol 1993, 92:323-327.
44. Kumar V, Kono DH, Urban JL, Hood L: The T-cell receptor repertoire and autoimmune diseases. Annu Rev Immunol 1989, 7:657-682.
45. Raine CS: Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 1984, 50:608-635.
46. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CAJ: Surface expression of alpha-4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993, 177:57-68.
47. Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990, 8:579-621.
48. Sedgwick J, MacPhee IAM, Puklavec M: Isolation of encephalitogenic CD4+ T cell clones in the rat Cloning methodology and interferon-y secretion. J Immunol Methods 1989, 121:185-196.
49. Ando DG, Clayton J, Kong D, Urban JL, Sercarz JL: Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989, 124:132-143.
50. Olsson T: Critical influences of the cytokine orchestration or the outcome of myelin antigen-specific autoimmunity in experimental autoimmune encephalomyelitis, multiple sclerosis. Immunol Rev 1995, 144:245-268.
51. Khoury SJ, Hancock WW, Weiner HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4 and prostaglandin E expression in the brain. J Exp Med 1992, 176:1355-1364.
52. Merrill JE, Kono DH, Clayton J, Ando DG, Hinton DR, Hofman FM: Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci USA 1992, 89:574-578.
53. Leonard JP, Waldburger KE, Goldman SJ: Prevention of • experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995, 181:381-386. Antagonism of II-212 action inhibits the onset of experimental autoimmune encephalomyelitis - a mouse model of multiple sclerosis.
54. Gijbels K, Brocke S, Menon S, Smith S, Narula S, O'Garra A, Steinman L: Administration of interleukin-4 enhances or ameliorates experimental autoimmune encephalomyelitis depending on the presence of endogenous interleukin-12. Proc Natl Acad Sci USA 1997, submitted.
55. Billiau A, Hereman H, Vanderkerckhove F, Dijkmans R, Sobis H, Muelepas E, Carton H: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J Immunol 1988, 140:1506-1510.
56. Doung TT, Finkelman F, Singh B, Strejan GH: Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J Neuroimmunol 1992, 53:101-107.
57. Panitch HS, Hirsch RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with gamma-interferon: exacerbations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
58. Ferber I, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG: Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5-7.
59. Krakowski M, Owens T: Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646.
60. Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988, 140:4245-4252.
61. Horowitz JB, Kaye J, Conrad PJ, Katz ME, Janeway CA: Autocrine growth inhibition of a cloned line of helper T cells. Proc Natl Acad Sci USA 1986, 83:1886-1890.
62. Alford EC, Kies MW, Suckling AJ: Experimental allergic encephalomyelitis - a useful model for MS. New York: Liss; 1984.
63. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan C-C, Wiggert B, Caspi RR: IFN-γ-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997, 158:5997-6005.
64. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu C, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK: IL-12-deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity 1996, 4:471-481.
65. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990, 172:1193-1200.
66. Karin N Mitchell, D.J, Brocke, S, Ling, N, Steinman, L: Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism, reduction of interferon-γ and tumor necrosis factor a production. J Exp Med 1994, 180:2227-2237.
67. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D et al.: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996, 379:343-346.
68. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, Ruddle NH, Steinman L: Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Internat Immunol 1990, 2:539-544.
69. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR: Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987, 166:1229-1244.
70. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD: Critical points of TNF action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997, 186:1585-1590.
71. Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith C: A lymphotoxin-β-specific receptor. Science 1994, 264:707-710.
72. Pober JS, Cotran RS: Cytokines, endothelial cell biology. Physiol Rev 1990, 70:427-451.
73. Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS: Recombinant human tumor necrosis factor increases mRNA levels, surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 1986, 83:446-450.
74. Bazzoni F, Beutler B: The tumor necrosis factor ligand, receptor families. New Engl J Med 1996, 334:1717-1725.
75. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G: TNF-alpha transgenic, knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997, 72:137-141.
76. Frei K, Eugster H-P, Bopst M, Constantinescu CS, Lavi E, Fontana A: Tumor necrosis factor α, lymphotoxin a are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997, 185:2177-2182.
77. Theophilopoulos AN: The basis of autoimmunity: part II genetic predisposition. Immunol Today 1995, 16:150-158.
78. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH: A critical role for lymphotoxin in EAE. J Exp Med 1997, in press.
79. Rajewsky K, Gu H, Kuhn R, Betz UA, Muller W, Roes J, Schwenk F: Conditional gene targeting. J Clin Invest 1996, 98:S51-S53.
80. Castano L, Eisenbarth GS: Type-1 diabetes: a chronic autoimmune disease of human, mouse and rat. Annu Rev Immunol 1990, 8:647-679.
81. Kikutani H, Makino S: The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 1992, 51:285-322.
82. Katz JD, Benoist C, Mathis D: T helper cell subsets in insulin-dependent diabetes. Science 1995, 268:1185-1188.
83. Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994, 12:227-257.
84. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997, 185:825-831.
85. Sarvetnick N, Shizuru J, Liggit D, Martin L, McIntyre B, Gregory A, Parslow T, Stewart T: Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature 1990, 346:844-847.
86. Stewart TA, Hullgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ: Induction of type I diabetes by interferon-α in transgenic mice. Science 1993, 260:1942-1946.
87. Campbell IL, Kay TWH, Oxbrow L, Harrison LC: Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD.Wehi mice. J Clin Invest 1991, 87:739-742.
88. Shehadeh NN, LaRosa F, Lafferty KJ: Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 1993, 6:291-300.
89. Bergman B, Haskins K: Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes 1994, 43:197-203,
90. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L: • Interleukin 12 administration induces T helper type 1 cells, accelerates autoimmune diabetes in NOD mice. J Exp Med 1995, 181:817-821. In this paper it is shown that IL-12 accelerates autoimmune diabetes in NOD mice, indicating that Th1 cells are pathologic in this disease.
91. Picarella DE, Kratz A, Li C-B, Ruddle NH, Flavell RA: Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. J Immunol 1993, 150:4136-4150.
92. Higuchi Y, Herrera P, Muniesa P, Huarte J, Belin D, Ohashi P, Aichele P, Orci L, Vassalli J-D, Vassalli P: Expression of a tumor necrosis factor a transgene in murine pancreatic β cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 1992, 176:1719-1731.
93. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea, H: Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin-1. Proc Natl Acad Sci USA 1990, 87:968-972.
94. Satoh J, Seino H, Abo T, Tanaka SI, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T et al.: Recombinant human tumor necrosis factor a suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989, 84:1345-1348.
95. Satoh J, Seino H, Shintani S, Tanaka SI, Ohteki T, Masuda T, Nobunaga T, Toyota T: Inhibition of type I diabetes in BB rats with recombinant human tumor necrosis factor-α, J Immunol 1990, 145:1395-1399.
96. Yang XD, Tisch R, Singer S, Cao Z, Liblau R, Schreiber R, McDevitt H: Effect of tumor necrosis factor a on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity, the diabetogenic process. J Exp Med 1994, 180:995-1004.
97. Grewal I, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA: Local expression of transgene encoded TNFα in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996, 184:1963-1974.
98. Kennedy MK, Torrance DS, Picha KS, Mohler KM: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992, 149:2496-2505.
99. Karpus WJ, Gould KE, Swanborg RH: CD4+ suppressor cells of autoimmune encephalomyelitis respond to T cell receptor-associated determinants on effector cells by interleukin-4 secretion. Eur J Immunol 1992, 22:1757-1763.
100. Cannella B, Gao YL, Brosnan C, Raine CS: IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996, 45:735-746.
101. Rott O, Fleischer B, Cash E: Interleukin-10 prevents experimental autoimmune encephalomyelitis in rats. Eur J Immunol 1994, 24:1434-1440.
102. Shaw MK, Lorens JB, Dhawan A, DalCanto R, Tse HY, Tran AB, Bonpane C, Eswaran SL, Brocke S, Sarvetnick N et al.: Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997, 185:1711-1714.
103. Mathisen PM, Yu M, Johnson JM, Drazba JA, Tuohy VK: Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997, 186:159-164.
104. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VJ: An altered peptide ligand mediates immune deviation, prevents autoimmune encephalomyelitis. Immunity 1995, 3:397-405.
105. Khoruts A, Miller SD, Jenkins MK: Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol 1995, 155:5011-5017.
106. Lafaille JJ, Van de Keere F, Hsu AL, Baron JL, Haas W, Raine CS, •• Tonegawa S: Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from disease. J Exp Med 1997, 186:307-312. T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in imunodeficient mice; this suggests that a regulatory cell is missing in immunodeficiency.
107. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL: Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995, 376:177-180.
108. Kuchroo VJ, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7-1, B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
109. Falcone M, Bloom BR: A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J Exp Med 1997, 185:901-907.
110. Shimada A, Charlton B, Rohane P, Taylor-Edwards C, Fathman CG: Immune regulation in type 1 diabetes. J Autoimmun 1996, 9:263-269.
111. Tian J, Atkinson MA, Clare-Salzer M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996, 183:1561-1567.
112. Rabinovitch A: Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 1994, 43:613-621.
113. Rapoport MJ, Jaramillo A, Zipris D, Lazrus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL: Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993, 178:87-89.
114. Mueller R, Krahl T, Sarvetnick N: Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996, 184:1093-1099.
115. Pennline KJ, Roque-Gaffney E, Monahan M: Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic (NOD) mouse. Clin Immunol lmmunopathol 1993, 71:169-174.
116. Wogensen L, Huang X, Sarvetnick N: Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J Exp Med 1993, 178:175-185.
117. Wogensen L, Lee M-S, Sarvetnick, N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 1994, 179:1379-1384.
118. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Mayazaki J, li S, Kudo E, Iwahana H, Hayashi Y, Sano T et al.: Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Internat Immunol 1994, 6:1927-1936.
119. Pakala SV, Kurrer MO, Katz JD: T helper 2 (Th2) cells induce •• acute pancreatitis and diabetes in immune-compromised non-obese diabetic (NOD) mice. J Exp Med 1997, 186:299-306. T helper 2 (Th2) cells induce acute pancreatitis and diabetes in immuno-compromised non-obese (NOD) mice; this suggests that a regulatory cell is missing in immunodeficiency.
120. Burstein HJ, Abbas AK: In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigens. J Exp Med 1993, 177:457-463.
121. De Wit D, Van Mechelen M, Ryelandt M, Figuereido AC, Abramowicz D, Goldman M, Bazin H, Urbain J, Leo O: The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J Exp Med 1992, 175:9-14.
122. Romball CG, Weigle WO: In vivo induction of tolerance in murine CD4+ cell subsets. J Exp Med 1993, 178:1637-1644.
123. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO: Antigen recognition in autoimmune encephalomyelitis, the potential for peptide-mediated immunotherapy. Cell 1989, 59:247-255.
124. Weiner HL: Oral tolerance: immune mechanisms and treatment • of autoimmune diseases. Immunol Today 1997, 18:335-343. A summary of a number of manuscripts on regulatory T cells which can inhibit autoimmune pathologies via the action of TGF-β.
125. Weiner HL: Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997, 48:341-351.
126. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A: The effect of antigen dose on CD4+ T cell phenotype development in an αβ-TCR-transgenic mouse model. J Exp Med 1995, 182:1579-1584.
127. Pearson Cl, van Ewijk W, McDevitt HO: Induction of apoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice. J Exp Med 1997, 185:583-599.
128. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington •• C, Raine CS, Hauser SL: Late complications of immune deviation therapy in a nonhuman primate. Science 1996, 274:2054-2057. This paper demonstrates that immune deviation from a cell-mediated imune response (Th1) to a humoral (Th2)-type response by soluble antigen can lead to delayed pathology instead of therapy in EAE in marmosets.
129. Powrie F, Mason D: OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset J Exp Med 1990, 172:1701-1708.
130. Powrie F, Leach MW, Mauze S, Menon S, Caddie LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562.
131. low via the action of TGF-β.
132. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalitis. Science 1994, 265:1237-1240.
133. + T cell lines which can inhibit both Th2 (and previously shown Th1) induced autoimmune pathologies via the action of TGF-β.
134. Groux H, O'Garra A, Bigler M, Rouleau M, De Vries J, Roncarolo •• M-G: Generation of a novel regulatory CD4+ T-cell population, which inhibits antigen-specific T-cell responses. Nature 1997, 389:737-742. This paper describes the isolation in vitro of a regulatory population of CD4* T cells which inhibits the proliferation of naive CD4+ T cells and the induction of inflammatory bowel disease in SCID mice via the action of TGF-ß and IL 10.
135. Fowell D, McKnight AJ1 Powrie F, Dyke R, Mason D: Subsets of CD4+ T cells and their roles in the induction and prevention of autoimmunity. lmmunol Rev 1991, 123:37-64.
136. Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD: CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993, 178:237-244.
137. Miller A, Lider O, Roberts A, Sporn MB, Weiner HL: Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor ßafter antigen-specific triggering. Proc Natl Acad Sd USA 1992, 89:421-425.
138. Han HS, Jun HS, Utsugi T1 Yoon JW: A new type of CD4+ •• suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmunity 1996, 9:331-339. This paper Identifies a suppressor T cell which inhibits diabetes in NOD mice.
139. Castedo M, Pelletier J1 Rossert R, Pasquier H, Villarroya H, Druet P: Mercury-induced autoreactive anti-class Il T cell line protects from experimental autoimmune encephalomyelitis by the bias of CDS+ antiergotypic cells in Lewis rats. J Exp Med 1993, 177:881-889.
140. Groux H, Bigler M1 De Vries J, Roncarolo M-G: lnterleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996, 184:19-29.
141. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, De Waal Malefyt R, De Vries JE, Roncarolo MG: High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994, 179:493-502.
142. Shull MM, Ormsby I1 Kier AB, Pawlowski S, Diebold PJ, Yin M1 Alien R, Sidman C, Proetzel G, Calvin D et al.: Targeted disruption of the mouse transforming growth factor-b1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
143. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10 deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
144. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
145. Miller JFAP, Heath WR: Self ignorance in the peripheral T-cell pool. Immunol Rev 1993, 133:131-150.